Literature DB >> 21088848

Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies.

Giovanna Cenacchi1, Valentina Papa, Papa Valentina, Marina Fanin, Fanin Marina, Elena Pegoraro, Pegoraro Elena, Corrado Angelini, Angelini Corrado.   

Abstract

Patients with myasthenia gravis (MG) with antibodies to muscle-specific receptor tyrosine kinase (MuSK) differ from acetylcholine receptor (AChR)-positive MG patients, as they frequently present with severe oculobulbar muscle weakness or with neck, shoulder, and respiratory muscle involvement. The neuromuscular junction (NMJ) has been confirmed to be the main target of both AChR- and MuSK-MG. However, histopathological investigation disclosed that muscle fiber atrophy was prevalent in AChR-MG, whereas mild myopathic changes and mitochondrial abnormalities were more frequently observed in MuSK-MG. As the pathogenetic mechanism in MuSK-MG remains unclear, this study investigated the submicroscopic pattern of muscle histopathology to establish a possible correlation between clinical involvement and subcellular morphological findings. Muscle biopsies from seven MuSK-MG patients and from seven patients with AChR-MG were analyzed by transmission electron microscopy. Myopathic and mitochondrial abnormalities were more prominent in MuSK-MG and show giant, swollen, and degenerated mitochondria with fragmented cristae. The most common changes in AChR-MG muscles were fiber atrophy, myofibrillar disarray, and Z-line streaming, consistent with mild neurogenic abnormalities. A different pathogenetic mechanism is emerging in MuSK-MG compared to AChR-MG. Mitochondrial abnormalities seem to be more prominent in MuSK-MG, whereas neurogenic atrophy is observed in AChR-MG.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088848     DOI: 10.1007/s00415-010-5823-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Authors:  Y Nemoto; S Kuwabara; S Misawa; N Kawaguchi; T Hattori; M Takamori; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

2.  Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.

Authors:  F Deymeer; O Gungor-Tuncer; V Yilmaz; Y Parman; P Serdaroglu; C Ozdemir; A Vincent; G Saruhan-Direskeneli
Journal:  Neurology       Date:  2007-02-20       Impact factor: 9.910

3.  Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes.

Authors:  A Rostedt Punga; K Ahlqvist; E Bartoccioni; F Scuderi; M Marino; A Suomalainen; H Kalimo; E V Stålberg
Journal:  Clin Neurophysiol       Date:  2006-06-05       Impact factor: 3.708

4.  MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns.

Authors:  D E Stickler; J M Massey; D B Sanders
Journal:  Clin Neurophysiol       Date:  2005-09       Impact factor: 3.708

5.  Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.

Authors:  Hirokazu Shiraishi; Masakatsu Motomura; Toshiro Yoshimura; Takayasu Fukudome; Taku Fukuda; Yoko Nakao; Mitsuhiro Tsujihata; Angela Vincent; Katsumi Eguchi
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

6.  MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.

Authors:  Maria Elena Farrugia; Matthew D Robson; Linda Clover; Phil Anslow; John Newsom-Davis; Robin Kennett; David Hilton-Jones; Paul M Matthews; Angela Vincent
Journal:  Brain       Date:  2006-05-03       Impact factor: 13.501

Review 7.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Authors:  Angela Vincent; John Bowen; John Newsom-Davis; John McConville
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

8.  Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR.

Authors:  S Martignago; M Fanin; E Albertini; E Pegoraro; C Angelini
Journal:  Neuropathol Appl Neurobiol       Date:  2009-02       Impact factor: 8.090

Review 9.  Clinical evaluation and management of myasthenia gravis.

Authors:  John C Keesey
Journal:  Muscle Nerve       Date:  2004-04       Impact factor: 3.217

10.  Are MuSK antibodies the primary cause of myasthenic symptoms?

Authors:  Duygu Selcen; Taku Fukuda; Xin-Ming Shen; Andrew G Engel
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

View more
  9 in total

1.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.

Authors:  Alexandra Pevzner; Benedikt Schoser; Katja Peters; Nicoleta-Carmen Cosma; Andromachi Karakatsani; Berthold Schalke; Arthur Melms; Stephan Kröger
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  Ultrastructural modifications in the mitochondria of hypoxia-adapted Drosophila melanogaster.

Authors:  Guy Perkins; Yu-hsin Hsiao; Songyue Yin; Jonathan Tjong; My T Tran; Jenna Lau; Jin Xue; Siqi Liu; Mark H Ellisman; Dan Zhou
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

5.  Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats.

Authors:  Jingwei Song; Xiaowen Lei; Wei Jiao; Yafang Song; Weijing Chen; Jinqiu Li; Zhiwei Chen
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

Review 6.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

7.  PPARα-targeted mitochondrial bioenergetics mediate repair of intestinal barriers at the host-microbe intersection during SIV infection.

Authors:  Katti R Crakes; Clarissa Santos Rocha; Irina Grishina; Lauren A Hirao; Eleonora Napoli; Christopher A Gaulke; Anne Fenton; Sandipan Datta; Juan Arredondo; Maria L Marco; Sumathi Sankaran-Walters; Gino Cortopassi; Cecilia Giulivi; Satya Dandekar
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-18       Impact factor: 11.205

8.  Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction.

Authors:  Stefan Hettwer; Shuo Lin; Stefan Kucsera; Monika Haubitz; Filippo Oliveri; Ruggero G Fariello; Markus A Ruegg; Jan W Vrijbloed
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

9.  The Myotonic Plot Thickens: Electrical Myotonia in Antimuscle-Specific Kinase Myasthenia Gravis.

Authors:  Marcus Magnussen; Ioannis Karakis; Taylor B Harrison
Journal:  Case Rep Neurol Med       Date:  2015-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.